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Objective: To investigate the effect of epicutaneously applied Diractin (ketoprofen in 
Transfersome gel) on pain induced by eccentric muscle contractions.
Methods: Three pilot studies which were subsequently pooled for a meta-analysis compared 
the efficacy of a single application of 25 mg ketoprofen in Diractin to 25 mg oral ketoprofen 
and placebo for the treatment of pain induced by 50 eccentric contractions of the elbow flexor 
muscles. In addition, the effect of multiple usage of up to 100 mg ketoprofen in Diractin bid 
over seven days on pain induced by walking down stairs with a total altitude of 200 meters 
was investigated.
Results: A single dose of 25 mg ketoprofen in Diractin after the elbow flexion exercise was 
significantly superior to placebo from 5 to 12 hours after treatment and also to oral ketoprofen at 
some time points after treatment. In contrast, oral ketoprofen was not different to placebo at any 
time after treatment. Multiple doses of up to 100 mg ketoprofen Diractin provided significant 
more pain relief than placebo on muscle pain induced by walking down stairs.
Conclusions: Eccentric exercise-induced muscle soreness was shown to be an appropriate 
acute pain model to evaluate the efficacy of nonsteroidal anti-inflammatory drugs applied epi-
cutaneously with Transfersome® carriers. Diractin proved to be efficacious in relieving pain 
from eccentric muscle contractions and muscle overexercise, respectively. The effect needs to 
be confirmed in a larger prospective clinical trial.
Keywords: ketoprofen, Transfersome®, epicutaneous application, eccentric muscle contraction, 
delayed onset muscle soreness
Introduction
Ketoprofen is a peripherally acting nonsteroidal anti-inflammatory drug (NSAID) 
belonging to the group of substituted 2-phenylpropionic acids.1 NSAIDs have the 
potential to cause gastrointestinal (GI) side effects such as GI bleeding in a dose-related 
manner. One approach to reducing these side effects has been to apply NSAIDs to the 
skin overlying affected joints and muscles.2–5
Diractin (ketoprofen in Transfersome® gel) is a new, carrier-based formulation 
for local application that has shown to reduce pain comparable to oral celecoxib in 
patients with knee osteoarthritis.6 Transfersome carriers are ultra-deformable lipid 
vesicles loaded with an active substance and applied epicutaneously in an aqueous 
preparation. Once the Transfersome carriers are on the skin, water from the preparation 
starts to evaporate and deprives carriers of their suspending medium. Transfersome® 
vesicles reaching their solubility limit are attracted by the higher water content in 
the skin, resulting in spontaneous migration of the drug-loaded carriers through the Drug Design, Development and Therapy 2009:3 144
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skin barrier.7 The cutaneous microcirculation cannot clear 
Transfersome® carriers due to their large size, resulting in 
high drug concentrations in local tissue with low systemic 
drug exposure.8
Diractin showed substantially higher drug concentration 
in target tissues such as muscle as compared to conventional 
topical products and oral ketoprofen, respectively, in muscle 
biopsy studies conducted in pigs.8
Eccentric exercise causes delayed-onset muscle soreness 
(DOMS) with pain peaking 24 to 48 hours after exercise.9,10 
An acute inflammatory reaction is considered one of the 
underlying mechanisms of DOMS.11,12 The muscle strain 
injury caused by eccentric contractions is characterized 
morphologically by microscopic damage to the muscle 
fibers (microtrauma).13 Neutrophils and tissue macrophages 
migrate to the damaged muscle tissue, clean up the debris 
of broken proteins, and then initiate the regeneration phase. 
Besides a classical inflammatory response, other mecha-
nisms of muscle adaptation and immunological responses 
in the muscle as well as epimysium might contribute to 
exercise-induced pain.14 The use of NSAIDs seems a reason-
able therapeutic approach to treat muscle pain induced by 
eccentric contractions.
This paper reports results from studies investigating the 
effect of epicutaneously applied Diractin® on pain induced 
by eccentric muscle contractions after single and multiple 
applications.
Methods
single dose application
The results of three pilot single-center, single-dose, 
randomized, double-blind, double-dummy, parallel-group, 
placebo- and active-controlled studies using the model 
of exercise-induced muscle pain were pooled for a meta-
analysis as the individual studies were underpowered to 
compare efficacy and safety of Diractin with placebo and 
oral ketoprofen. All three pilot studies used the same study 
design, equipment, and application instructions. Studies were 
performed in accordance with the Declaration of Helsinki 
and the International Conference on Harmonization of Good 
Clincial Practice. Study protocols were approved by the 
relevant institutional review boards.
Subjects provided written informed consent before any 
study-specific activity was performed. Two hundred ninety-
five healthy men and women aged 18 to 45 years were 
enrolled in the studies. They had to refrain from any strenuous 
or new physical activities and comply with the respective 
study protocol while participating in the studies. Moreover, 
subjects had to be naïve to the exercise so that they could 
not have resistance trained or performed work that required 
similar exercise for six months before enrolling in the study. 
Exclusion criteria focused on avoiding any untoward risk 
for the study participants and potential interference with the 
study objectives. Study procedures were performed at four 
visits. At Visit 1, subjects’ eligibility was assessed by medical 
history and physical examination. Studies used comparable 
inclusion/exclusion criteria. Within two weeks after Visit 1, 
subjects completed the exercise regimen (Visit 2) consist-
ing of 50 consecutive maximal eccentric contractions of the 
elbow flexor muscles of the nondominant arm. For exercise, 
subjects were seated on a modified preacher’s bench with 
the nondominant upper arm resting on a padded support, the 
wrist fixed between two padded rollers of the exercise lever 
and the forearm in a fully flexed position. For each eccentric 
action, the investigator staff had pulled down on the lever, 
forcing the subjects forearm into a fully extended position as 
the subjects exerts maximum resistance. Subjects reporting 
pre-exercise soreness/pain of 10 mm on a visual analogue 
scale (VAS) at Visit 2 were excluded from the study. The 
Visit 2 exercise was performed in the evening. Approxi-
mately 32 hours later, at Visit 3, following an overnight fast, 
subjects meeting all continuation criteria and reporting at 
least 50 mm VAS post-exercise soreness/pain received either 
topical or oral ketoprofen (25 mg each) and oral or topical 
placebo, respectively. Subjects were fed a standardized meal 
and remained at the study center for the entire observation 
period. Subjects rated their muscle soreness/pain intensity 
prior to performing the exercise, immediately prior to treat-
ment, and at hourly intervals for 12 hours after treatment. At 
the end of these assessments, subjects provided an overall 
rating of the study medication. At the final visit (Visit 4), 
approximately four days after Visit 3, safety and tolerability 
of the treatments were assessed.
No primary efficacy parameters were specified in the 
protocols due to the exploratory nature of the studies. 
Muscle soreness/pain intensity was assessed using VAS 
and categorical scale (CAT) by completing two actions of 
elbow flexion and relaxation while holding a 2-lb dumbbell 
(approximately 0.9 kg). Results for categorical pain intensity 
difference (CATPID) and visual analogue scale pain intensity 
difference (VASPID) from baseline (immediately prior to 
treatment at Visit 3) to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 
12 hours after treatment were determined in the same way in 
all three studies. The 100 mm horizontal VAS line was labeled 
“no soreness/pain” on the left (corresponding to "0") and “very, 
very sore/painful” on the right (corresponding to “100”). Drug Design, Development and Therapy 2009:3 145
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Categorical ratings of muscle soreness/pain were obtained on 
a 10-point ordinal rating scale from 0 = none to 9 = extremely 
intense.
The meta-analysis was performed for the intent-to-treat 
populations, ie, all subjects that received study medication. 
The overall statistics were obtained from a meta-analysis of 
CATPID and VASPID scores with treatment and baseline 
pain as fixed effects, and study as a random effect. Each study 
was allowed an individual variance component. Homogene-
ity in mean responses of the studies was assessed by testing 
the significance of study variance component in the random 
effect model. In matters of least-squares (LS) means compari-
son, the interaction terms drug-by-study and drug-by-baseline 
were not significant (p  0.05), and subsequently dropped 
from the final model. P-values are obtained from testing the 
equality of all three groups. LS means and standard errors are 
obtained from an analysis of covariance model with treatment 
and baseline pain as factors. The differences are that of LS 
means. P-values are unadjusted, and obtained from testing 
the equality of two groups.
Multiple dose application
Nineteen subjects were included in this pilot study to 
investigate the efficacy of multiple dosages of Diractin (bid 
over seven days) for the treatment of exercise-induced muscle 
pain. To induce muscle pain, the subjects walked down stairs 
using twelve consecutive runs of 18 m difference in total 
altitude per run (120 stairs with each stair 15 cm high). This 
corresponds to a total altitude of approximately 200 m.
Eligible subjects came in at the day after exercise and were 
randomly allocated to two subgroups which received 100 mg 
ketoprofen in Diractin bid either on the left or right target 
muscle (thigh). The subjects were asked to apply the product 
open (nonocclusively) over the entire surface of either the left 
or the right thigh. The contralateral leg was used as (untreated) 
control. The primary target area for all subjects was the thigh. 
If in some subjects the calf became symptomatic, Diractin 
was also administered epicutaneously to the entire surface of 
the left or right calf. Again, the contralateral calf was used as 
untreated control. Categorical ratings of muscle soreness/pain 
were recorded on a 10-point ordinal rating scale (0 = none to 
9 = extremely) twice daily in a diary, immediately before study 
drug application. For statistical testing, the sum of categori-
cal pain scores for the treated muscle were compared to the 
untreated control muscle using the Wilcoxon test. Nonpara-
metric testing was chosen due to the small sample size and 
since it was assumed prospectively that normal distribution 
of data is not guaranteed.
Results
single dose application
The demographic data between the three treatment groups 
was comparable with an age range of 18 to 45 and the 
majority of subjects being males (Table 1). Also baseline 
pain was comparable between the treatment groups with 
CAT scores around 6.4 and VAS scores between 70.5 and 
73.7 mm (Table 2).
The estimated hourly VASPID and CATPID results 
from one to 12 hours after treatment for Diractin (IDEA-
033) versus placebo are presented in Figures 1a and 1b, for 
Diractin® (IDEA-033) versus oral ketoprofen in Figures 2a 
and 2b, and for oral ketoprofen versus placebo in Figures 3a 
and 3b. Mean VASPID for 25 mg ketoprofen in Diractin 
versus placebo increased over time reaching a plateau of sig-
nificant differences between Diractin and placebo from five 
to 12 hours after treatment (Figure 1a). Similar results were 
determined for mean CATPID (Figure 1b). Mean VASPID 
for 25 mg ketoprofen in Diractin versus oral ketoprofen 
were significantly different only at 12 hours after treatment 
(Figure 2a), whereas mean CATPID showed significant 
difference between Diractin and oral ketoprofen from 
seven to 12 hours after treatment (Figure 2b). No significant 
differences in mean VASPID and CATPID between oral 
ketoprofen and placebo were determined at any time after 
treatment (Figures 3a and 3b).
Multiple dose application
Nineteen subjects were included (Table 1). The calf was 
treated in nine subjects. The subjects documented higher 
pain scores for the calf than for the thigh, maximum 
pain was observed within 24 to 48 hours after exercise 
Table 1 Demographics of study populations
Variable Placebo Diractin® Oral ketoprofen
single dose study
number of subjects 88 118 89
Age
  Mean (Range) 26.3 (18–45) 26.6 (18–44) 26.4 (18–45)
sex
  Female/Male 34/54 51/67 33/56
Multiple Dose study
number of subjects 19
Age
  Mean (Range) 23.4 (18–44)
sex
  Female/Male 10/9Drug Design, Development and Therapy 2009:3 146
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(average categorical pain score at time of maximum pain 
for untreated thigh: 2.6 ± 2.2; for untreated calf: 5.1 ± 1.9). 
The average sum of categorical pain scores documented 
for the treated thighs (n = 19) was 12.4 (range 0 to 29) and 
14.8 (range 0 to 42) in the untreated thighs. The sum of pain 
scores was significantly lower in the treated thighs than in 
the untreated thighs (Wilcoxon p-value = 0.039; Table 3). 
For the calf (n = 9), the average sum of pain scores docu-
mented for the treated calves was 29.4 (range 13 to 55) 
and in the untreated 32.9 (range 6 to 65). The difference 
between treated and untreated areas was not statistically 
significant (Wilcoxon p-value = 0.359) probably due to 
the small sample size.
Discussion and conclusions
Different pain models have been developed for evaluating 
the efficacy of topical and oral NSAIDs. Besides defined pain 
situations in patients, eg, after surgery or tooth extraction, 
additional models were explored that would be more specific 
to muscular pain.
Experimental pain resulting from continuous pressure 
infusion of phosphate-buffered low pH solution (pH 5.2) 
into the belly of the radial flexor carpi muscle induced a 
localized dull-aching or stinging muscle pain sensation.15 
However, it remained unclear whether this experimental 
induction of muscle pain was predictive for actual muscle 
pain. Therefore, the induction of muscle soreness/pain by 
controlled, standardized eccentric contractions producing 
DOMS was explored. DOMS is defined as skeletal muscle 
discomfort that peaks 24 to 48 hours after exercise.1 At that 
time, a significant increase in prostaglandin E2 was observed, 
suggesting that acute inflammation is one of the underlying 
mechanisms of DOMS.11,12 More recent studies indicate that a 
classical inflammatory reaction might not be the main reason 
Table 2 Mean pain scores before treatment for single dose application studies and the corresponding 95% confidence intervals of 
difference (ci) between treatment groups
Variable Placebo Diractin® Oral ketoprofen CI Plac. vs Diractin® CI Plac. vs Oral CI Diractin® vs Oral
categorical pain scale 6.36 6.54 6.41 (-0.12; 0.49) (-0.27; 0.36) (-0.16; 0.44)
Visual analog scale (mm) 70.6 73.7 72.3 (-0.67; 7.00) (-2.32; 5.80) (-2.40; 5.25)
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Figure 1a estimated mean hourly visual analogue scale pain differences (VAsPiD) 
between 25 mg ketoprofen in Diractin® and placebo from 1–12 hours after treatment 
(mean differences and 95% ci).
Abbreviation: ci, confidence interval.
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Figure 1b estimated hourly categorical pain intensity differences (cATPiD) between 
25 mg ketoprofen in Diractin® and placebo from 1–12 hours after treatment (mean 
differences and 95% ci)
Abbreviation: CI, confidence interval.Drug Design, Development and Therapy 2009:3 147
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Figure 2a estimated mean hourly visual analogue scale pain differences (VAsPiD) 
between 25 mg ketoprofen in Diractin® and 25 mg oral ketoprofen from 1–12 hours 
after treatment (mean differences and 95% ci).
Abbreviation: ci, confidence interval.
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Figure 2b estimated hourly categorical pain intensity differences (cATPiD) between 
25 mg ketoprofen in Diractin® and 25 mg oral ketoprofen from 1–12 hours after 
treatment (mean differences and 95% ci).
Abbreviation: CI, confidence interval.
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Figure 3a estimated mean hourly visual analogue scale pain differences (VAsPiD)   
between 25 mg oral ketoprofen and placebo from 1–12 hours after treatment (mean 
differences and 95% ci).
Abbreviation: ci, confidence interval.
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Figure 3b estimated hourly categorical pain intensity differences (cATPiD) between 
25 mg oral ketoprofen and placebo from 1–12 hours after treatment (mean differences 
and 95% ci).
Abbreviation: ci, confidence interval.Drug Design, Development and Therapy 2009:3 148
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Table 3 sum of categorical pain intensity differences after multiple use
Muscle Target area N Mean SD Median (Range) P – value (Wilcoxon)
Thigh
Treated 19 12.4 10.3 13 (0–29)
0.039
not treated 19 14.8 13.1 12 (0–42)
calf
Treated 9 29.4 14.9 26 (13–55)
0.359
not treated 9 32.9 18.5 35 (6–65)
for DOMS, but other mechanisms of muscle adaptation and 
changes in immunological parameters in the epimysium 
might contribute to this process.14 The controversy between 
several studies might also be related to the effects of muscle 
biopsies itself.14
The effect of NSAIDs on muscle pain induced by eccentric 
contractions is still controversial. A lack of efficacy of oral 
NSAID treatment was reported for flurbiprofen and ibupro-
fen.16,17 The influence of flurbiprofen on subjective soreness 
was investigated in six healthy young men.16 The subjects 
performed one concentric and two eccentric work bouts of 
30 min at 80% of the individual maximal work load on the 
bicycle ergometer. No influence of 50 mg flurbiprofen tid on 
subjective soreness was reported. The influence of 400 mg 
ibuprofen tid on active range of motion, perceived pain, and 
peak concentric torque measurements of the nondominant arm 
was assessed in 40 subjects in a randomized, double-blinded, 
repeated measures design.17 Subjects performed an eccentric 
exercise protocol of the elbow flexors. No differences among 
treatments were observed for any of the dependent variables 
at any time up to 96 hours after the exercise.
In contrast, a randomized, double-blind, placebo-controlled 
crossover study of 200 mg oral naproxen tid for 10 days 
indicated superiority of naproxen to placebo in improving 
objective recovery as per magnetic resonance imaging results 
and effects on thigh soreness in particular during the first 
four days after exercise.18 Subjects performed 10 sets of 
7–10 eccentric actions with each quadriceps femoris muscle 
with a load equal to 85% of the eccentric one repetition 
maximum. Study drug treatment began immediately after 
exercise. In a randomized, double-blind, placebo-controlled 
parallel-group study, the influence of 100 mg ketoprofen 
in a pluronic lecithin organogel applied tid on DOMS was 
investigated in 32 young healthy men.19 Subjects performed 
a leg extension and flexion exercise program designed to 
create DOMS in quadriceps muscles. Subjects were randomly 
assigned to receive any combination of topical ketoprofen 
or placebo gel to their right and left quadriceps immediately 
following the exercise. Within-subjects analysis (n = 16) 
showed a significant reduction in DOMS scores in legs 
receiving topical ketoprofen compared with legs receiving 
placebo (P = 0.002 at 48 hours, and P  0.001 at 24 and 
48 hours combined). Between-subjects analysis (n = 16) 
showed a marginally significant reduction in DOMS scores at 
48 hours (P = 0.05 in right legs and P = 0.053 in left legs).
The studies published varied not only with respect of the 
NSAID investigated, but also whether study drug was applied 
immediately after exercise or at peak of the soreness. We 
therefore decided to explore the various options in different 
settings, eg, single and multiple dosing, using oral ketopro-
fen as an active comparator, or investigating the therapeutic 
effect of Diractin® at different muscular regions, ie, elbow 
flexor muscles or thigh and calf muscles, respectively.
A single dose of 25 mg ketoprofen in Diractin was 
significantly superior to placebo in treating muscle pain 
induced by eccentric contractions and as expressed by mean 
VASPID and CATPID from five to 12 hours after treatment 
and also to 25 mg oral ketoprofen at some time points after 
treatment. In contrast, a single dose of 25 mg oral ketoprofen 
was statistically not different to placebo at any time after treat-
ment. Diractin application was also effective as compared to 
untreated controls after multiple applications. The appropriate 
dose and treatment regimen still needs to be confirmed in a 
larger randomized, controlled, prospective clinical trial.
DOMS was shown to be an appropriate pain model for 
evaluating the therapeutic effect of epicutaneous Diractin® on 
acute muscle pain. The results indicate that Diractin® appears 
to be a valuable option for treating musculoskeletal pain.
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